Abstract
Introduction: Prognostic scores have limitations in their predictive power. Role of biomarkers has been proposed as a means of improving the predictive ability of such scores.
Objective: To evaluate the utility of biomarkers of systemic inflammation on their own and in combination with prognostic scores for mortality and/or severe complications at 30days.
Methodology: Prospective observational multicenter study that included 4 hospitals. The cohort was divided into an internal cohort(2 hospitals)and an external cohort(2 hospitals). SCAP, PSI and CURB65 severity scores were analyzed as well as CPR, PCT, and proADM biomarkers. Biomarkers and scores were compared in relation to mortality and/or severe complications(shock, ICU, mechanical ventilation)at day 30. Logistic regression techniques were used for mortality and/or severe complications at 30days, and predictive capacity of each score and biomarker was calculated based on AUC. It was analyzed if the inclusion of each biomarker would improve the predictive capacity of scores.
Results: 956 patients were included;462 in internal and 494 in external sample. Table1 shows the predictive capacity of severity scores and biomarkers unadjusted for our outcome of interest. AUC values of the adjusted models(scores+biomarkers)are shown inTable2.
Conclusions: Combination of proADM with prognostic scores improved the predictive ability of the latter on both cohorts.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA4535.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019